61
David Alker, Peter E Cross: Piperidine and pyrrolidine derivatives. Pfizer, Peter C Richardson, Paul H Ginsburg, Garth Butterfield, September 6, 1994: US05344835 (24 worldwide citation)

According to the invention there is provided a compound of formula (I): R.sup.1 --O(CH.sub.2).sub.m A(CH.sub.2).sub.n XR or a pharmaceutically acceptable salt thereof, wherein R.sup.1 is a group of formula (a or b) where Z is --(CH.sub.2).sub.2-, --CH.dbd.CH--, --CH.sub.2 --S-- or --CH.sub.2 --O--; ...


62
Robert G Pendleton: .alpha..sub.2 -adrenergic receptor antagonists as modifiers of gastrointestinal motility. William H Nicholson, Michael C Sudol, June 16, 1987: US04673680 (24 worldwide citation)

Selective .alpha..sub.2 -adrenergic receptor antagonists are effective in modifying gastrointestinal motility in a manner useful in the treatment of colonic spasm, irritable bowel syndrome and constipation.


63
Peter E Cross, Alexander R MacKenzie: Pyrrolidine derivatives. Pfizer, Peter C Richardson, Paul H Ginsburg, Seymour G Bekelnitzky, August 3, 1993: US05233053 (24 worldwide citation)

Compounds of the formula ##STR1## wherein R, Y and R.sup.1 are as defined in the specification. These compounds are muscarinic receptor antagonists which are selective for smooth muscle muscarinic sites over cardiac muscarinic sites, and are useful in the treatment of diseases associated with altere ...


64
Mitsuaki Ohta, Takeshi Suzuki, Jun ya Ohmori, Keiji Miyata, Isao Yanagisawa: Method of treatment of intestinal diseases. Yamanouchi Pharmaceutical, Burgess Ryan and Wayne, August 20, 1996: US05547961 (24 worldwide citation)

A method is provided for the treatment of hypersensitive intestinal diseases (irritable bowel syndrome) comprising the administration of a tetrahydroimidazopyridine derivative of the formula: ##STR1## wherein either one of X and Y is nitrogen and the other one is a radical represented by the formula ...


65
Geoffrey Gymer, Kiyoshi Kawamura, Sachiko Mihara, Mikio Morita, Alan Stobie, Chikara Uchida, Seiji Nukui: Oxo or oxy-pyridine compounds as 5-HT4 receptor modulators. Pfizer, Gregg C Benson, Frank W Forman, December 27, 2005: US06979690 (23 worldwide citation)

This invention provides compounds of the formula (I) and (II): or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1 is hydrogen or halo; R2 and R3 are independently hydrogen or C1-6 alkyl; R4 and R5 are independently hydrogen or C1-6 alkyl; ...


66
Jaswant S Gidda, John M Schaus: Isoxazole derivatives for the treatment of irritable bowel syndrome. Eli Lilly and Company, Douglas J Taylor, July 18, 1995: US05434174 (22 worldwide citation)

Methods of treating Irritable Bowel Syndrome (IBS) using a series of isoxazole derivatives that have both 5-HT1A agonist and M1 muscarinic activities, and formulations adapted for the treatment of IBS comprising those derivatives.


67
Thomas F Burks, Cynthia A Williams: Treatment for irritable bowel syndrome. Research Corporation Technologies, Scully Scott Murphy & Presser, August 17, 1993: US05236901 (22 worldwide citation)

The present invention relates to a method of treatment of functional bowel disease in mammals. More specifically, this invention contemplates prophylaxis and treatment of functional bowel disease in mammals by the administration of antagonists of corticotropin releasing factor. The present invention ...


68
Alverdy John C: Modulation of microbial pathogen-host cell interactions. The University Of Chicago, Alverdy John C, MERKEL William K, December 14, 2006: WO/2006/132963 (22 worldwide citation)

The invention provides methods of screening for modulators of microbial PA-I lectin/adhesin activity, including modulators of PA-I expression, as well as the modulators so identified, pharmaceutical compositions and kits containing such modulators. These modulators include soluble and membrane-bound ...


69
Kato Tomoki, Kon I Kana, Yuki Yohei, Ando Kazuo: Sulfonyl benzimidazole derivatives. Pfizer Japan, Kato Tomoki, Kon I Kana, Yuki Yohei, Ando Kazuo, Pfizer, FULLER Grover F Jr, September 13, 2007: WO/2007/102059 (22 worldwide citation)

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R1, R2 ,R3, R4, R5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 recept ...


70
Theoharis C Theoharides: Method of treating mast cell activation-induced diseases with a proteoglycan. Theoharis C Theoharides, Melvin Blecher, Law Offices of Dr Melvin Blecher, February 10, 2004: US06689748 (22 worldwide citation)

The invention provides a method for preventing and treating the harmful biological effects of biochemicals secreted from activated mast cells in the organism of warm blooded animals and more especially human beings, said effects being associated with allergy (including but not limited to allergic co ...



Click the thumbnails below to visualize the patent trend.